AZR
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -4.52 | $0 | $0 |
| 2026 Q2 | -11.25 | $0 | -$6M |
| 2026 Q1 | -1.48 | $0 | -$2M |
| 2025 Q4 | -1.80 | $0 | -$1M |